The Health 'Shadow War' Around Menopause: This Test Helps You Clear 'Landmines' Early — Endometrial Cancer Edition
Women's health is like a "protracted battle" that requires careful guarding. This is especially true during the perimenopausal stage around ages 45–55, when menstrual cycles become irregular, hormone levels ride a roller coaster, and various "minor ailments" tend to surface. During this time, the risk of gynecologic tumors (such as cervical cancer, endometrial cancer, and ovarian cancer) quietly increases, yet traditional screening methods (like HPV testing and TCT) often encounter "trouble": cervical atrophy makes sampling difficult, cellular morphology becomes "blurry" and hard to interpret, and even "undetectable" false negatives may occur, delaying diagnosis.
However, in recent years, a new technology called "CISENDO® methylation reagent testing" has emerged. It's like installing a "precision alarm" in cells, specifically capturing the "invisible signals" of early cancer, helping perimenopausal women detect health risks earlier and more accurately. Today, let's discuss in plain language what makes this test so powerful.
I. DNA Methylation: The Cell's "Invisible Switch" Harboring Cancer's "Little Secrets"
To understand this test, we first need to understand a concept — DNA methylation. Simply put, it's like putting a "hat" or "label" on DNA molecules to control gene "switches."
As an analogy, our cells contain many "good genes" (such as tumor suppressor genes) and "bad genes" (such as oncogenes). Under normal conditions, the body gives "good genes" a "green light" (maintaining low methylation), allowing them to work properly and suppress uncontrolled cell growth. Simultaneously, "bad genes" get a "red light" (high methylation), preventing them from causing trouble. But if a cell is infected by a virus (such as HPV) or turns "bad," this "switch system" goes haywire — the "green light" on good genes is forcibly turned off (abnormal hypermethylation), preventing them from controlling cell growth, while the "red light" on bad genes is turned off (hypomethylation), giving bad genes a clear path and setting the stage for uncontrolled cell proliferation.
Most critically, this "switch disruption" often occurs years before a tumor becomes visible to the naked eye! It's as though while cancer is "secretly stepping on the gas," methylation has already "lit up the alarm." For example, in cervical cancer, persistent infection with high-risk HPV (such as types 16/18) damages the tumor suppressor genes in cervical cells (such as PAX1, JAM3), causing their methylation "switches" to become stuck and unable to close. At this point, even before cells have grown into "bad actors," the methylation abnormality has already been secretly "written" into the DNA.
II. Difficulty in Perimenopausal Screening? Traditional Methods Have "Two Major Fatal Flaws"
For perimenopausal women, gynecologic screening is like searching for an "important notice" in an "old neighborhood" — difficult and prone to omissions.
Premenopausal challenges: Estrogen is still "causing trouble." Endometrial cell turnover slows but continues to work, which brings problems. Some endometrial cancer symptoms (such as bleeding) may be attributed to perimenopause (the period from menstrual irregularity to one year after menstrual cessation, also known as the menopausal transition or climacteric) and overlooked, or transvaginal ultrasound can only detect "shadows," unable to distinguish "benign" from "endometrial cancer." Curettage causes pain and hesitation, and due to varying physician experience and the limitations of blind scraping, there is a coin-flip between "scraping it" and "missing it" — with high risks of missed diagnosis and repeat procedures.
Postmenopausal challenges: As estrogen recedes, the cervix gradually atrophies, cells decrease in number and become "old." During sampling, it's like searching for "key letters" in a pile of "old newspapers" — it's easy to miss lesional cells.
Endometrial cancer: Endometrial tissue also becomes hardened and fibrotic, "hiding" lesions. Not only does imaging show only a thin layer, but curettage also has difficulty reaching the tissue, making imaging, pathology, and gynecologic assessment more challenging.
III. CISENDO® Testing: The "Black Technology" That Decodes "Invisible Signals"
The core of CISENDO® methylation testing is "precision code-reading" — using fluorescence-based quantitative PCR technology to carefully examine specific tumor suppressor genes (such as CDO1 and CELF4) in cervical exfoliated cells to determine whether their methylation "switches" have been abnormally turned off.
How powerful is this technology? Let's break it down by scenario:
For Premenopausal Women:
Avoiding "Unnecessary Ordeals" — If you've searched online and found symptoms resembling endometrial cancer, or if a transvaginal ultrasound (TVS) shows abnormalities, don't panic! Discuss with your physician about doing a non-invasive CISENDO® test first, before deciding whether to proceed immediately with curettage or hysteroscopy. This way, you can first understand the "activity level" of the lesion, enabling more thorough subsequent examinations. For example, if you have bleeding symptoms and an abnormal TVS but the tumor suppressor gene methylation is normal, it may indicate only a "benign" condition — the cells haven't been "corrupted" yet. If methylation is abnormally high, it suggests the lesion is "secretly upgrading" and requires prompt intervention. This approach reduces unnecessary D&C or hysteroscopic procedures, protecting uterine function.
For Postmenopausal Women: Missed Diagnosis? No Way!
Even if the endometrium has atrophied, cells are sparse, and many "old, spent cells" are mixed in, making the endometrium appear as a thin layer that helps cancer cells hide — CISENDO® testing can still precisely "uncover" the lesion's "tell-tale trail" — because it examines gene "switches," not cell appearance. Clinical data shows that for endometrial cancer screening in postmenopausal women, its detection rate and specificity are significantly higher than traditional imaging, with high "concordance" with pathological biopsy. A positive CISENDO® result enables hysteroscopists to examine more carefully, significantly reducing the risk of missed diagnosis.
Full-Cycle Protection: From Screening to "Surveillance"
It's not just a "one-time test" — after progestin therapy or partial hysterectomy, it can "monitor" for lesion recurrence. If methylation levels decrease after treatment, it indicates that "bad cells" have been cleared and the prognosis is good. If levels remain persistently elevated, residual disease may be present, requiring prompt re-evaluation. From screening to follow-up, it provides perimenopausal women with a "safety net."
IV. Early Detection, Early Peace of Mind: How Important Is This for Women?
World Health Organization data shows that approximately 500,000 women worldwide develop cervical cancer annually, with 70% in developing countries. In China, perimenopausal women, due to screening difficulties and special physiology, have become a "vulnerable area" in cervical cancer prevention and control.
The popularization of CISENDO® testing is like adding "reinforced walls" to this "vulnerable area":
(1) For ourselves: Fewer unnecessary tests, fewer unnecessary surgeries — saving worry and money;
(2) For physicians: More accurate "molecular indicators" for more confident diagnosis and clearer treatment direction;
(3) For society: Early detection and early treatment can reduce much of the suffering of advanced cancer, helping advance "Healthy China."
In closing: The perimenopausal period is not a "health blind spot" but a "critical window for protection"
The years around menopause are a "turning point" for the body and a "golden period" for health protection. We used to think "as we age, there's nothing to detect," but now with technologies like CISENDO®, we can detect potential risks earlier and more accurately.
Health is not something to "worry about only when you're old" — it's something to "prevent starting now." If you are a woman aged 45–55, or have family members in this age group, consider learning more about "methylation testing" — it may be the key weapon that helps you "clear mines" ahead of time.
After all, the best "amulet" is an "alarm" that can detect problems early!
Beijing Origin CISPOLY Biotechnology Co., Ltd. is a technology-driven enterprise committed to health innovation. As a pioneer in the field of early gynecologic oncology diagnosis, CISPOLY has developed early-detection products for cervical cancer, endometrial cancer, and ovarian cancer using proprietary technologies and patent-protected biomarkers, filling a critical gap in the field.
As women pay increasing attention to their own health, the women's health market holds great potential. Beyond the early screening and diagnosis product pipeline for gynecologic oncology, CISPOLY will continue to build additional women's health product lines, establishing itself as a technology-innovation-leading enterprise in the women's health market.